Results 221 to 230 of about 30,070 (260)
Journal of the American Society of Echocardiography, 2019 Myeloproliferative neoplasm (MPN) has been associated with pulmonary hypertension (PH) on the basis of small observational studies, but the mechanism and clinical significance of PH in MPN are not well established.
Jiwon Kim +2 more
exaly +2 more sources
Update on JAK2 inhibitors in myeloproliferative neoplasm
Therapeutic Advances in Hematology, 2011 Since the discovery of mutant Janus Kinase 2 ( JAK2), JAK2V617F, in a major proportion of myeloproliferative neoplasm (MPN) patients, there has been a flurry of activity in the development of JAK2 inhibitors.
Maya Koren-Michowitz
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Thrombosis in Myeloproliferative Neoplasms
Seminars in Thrombosis and Hemostasis, 2014Thrombotic events are very frequent and represent the main cause of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), mainly polycythemia vera and essential thrombocythemia. Pathogenesis of blood clotting activation in these diseases is multifactorial, and it involves various abnormalities of
Falanga, A, Marchetti, M
openaire +3 more sources
Pediatric Myeloproliferative Neoplasms
Clinics in Laboratory Medicine, 2021Myeloproliferative neoplasms can present early in life and may present a diagnostic challenge. Very few studies have focused on the diagnosis, prognosis, and therapy for pediatric myeloproliferative neoplasms. This article focuses on chronic myeloid leukemia, essential thrombocythemia, polycythemia vera, and primary myelofibrosis in children.
Farah, El-Sharkawy +1 more
openaire +2 more sources
Myeloproliferative Neoplasms with Monocytosis
Current Hematologic Malignancy Reports, 2021Myeloproliferative neoplasms (MPN) are a heterogeneous group of hematopoietic stem cell neoplasms comprising of polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) that share driver mutations (JAK2/CALR/MPL) resulting in constitutive activation of JAK/STAT and other signaling pathways.
Erika Morsia, Naseema Gangat
openaire +2 more sources
Single-Cell Exome Sequencing and Monoclonal Evolution of a JAK2-Negative Myeloproliferative Neoplasm
Cell, 2012 SummaryTumor heterogeneity presents a challenge for inferring clonal evolution and driver gene identification. Here, we describe a method for analyzing the cancer genome at a single-cell nucleotide level.
Yong Hou, Bo Zhang, Xun Xu
exaly +2 more sources
Inflammation and myeloproliferative neoplasms
Journal of Autoimmunity, 2017Myeloproliferative neoplasms (MPN) include three main entities: Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF). MPN represent a unique model of the relationship between the clonal development of a hematologic malignancy and chronic inflammation.
F. Lussana, A. Rambaldi
openaire +2 more sources
Diagnostic Approach to Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms
Advances in Anatomic PathologyThe International Consensus Classification (ICC) updated in 2022 the World Health Organization (WHO) classification of hematopoietic tumors (2016 revision of the 4th edition WHO classification). Although the major categories of myeloid neoplasms remained unchanged from the prior WHO classification, many disease entities including those in the ...
Sonam Prakash, Attilio Orazi
openaire +2 more sources
Genetics of the myeloproliferative neoplasms
Current Opinion in Hematology, 2011Since the discovery of the JAK2V617F mutation in 2005, an increasing number of somatic and germline genetic events responsible for myeloproliferative neoplasm (MPN) pathogenesis have been uncovered. The purpose of this review is to outline the most recent discoveries of the genetic alterations found in patients with MPNs.In addition to the JAK2V617F ...
openaire +2 more sources